Free Trial

Viatris (VTRS) Stock Forecast & Price Target

$10.39
-0.02 (-0.19%)
(As of 05/28/2024 ET)

Viatris - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
Based on 3 Analyst Ratings

Consensus Price Target

$11.00
5.87% Upside
High Forecast$13.00
Average Forecast$11.00
Low Forecast$9.00
TypeCurrent Forecast
5/29/23 to 5/28/24
1 Month Ago
4/29/23 to 4/28/24
3 Months Ago
2/28/23 to 2/28/24
1 Year Ago
5/29/22 to 5/29/23
Consensus Rating
Sell
Sell
Sell
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
6 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.00$11.00$10.33$12.67
Forecasted Upside5.87% Upside5.80% Upside8.01% Upside14.61% Upside
Get Viatris Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.

VTRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VTRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Viatris Stock vs. The Competition

TypeViatrisMedical CompaniesS&P 500
Consensus Rating Score
1.33
2.70
2.49
Consensus RatingSellModerate BuyHold
Predicted Upside5.06% Upside804.72% Upside10.29% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/28/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$11.00 ➝ $13.00+9.80%
10/23/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$13.00 ➝ $9.00-3.23%
6/23/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual Weight ➝ Underweight$11.00+9.45%
2/17/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$16.00 ➝ $14.00+20.17%
1/27/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$13.00 ➝ $15.00+28.87%
11/15/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$13.00 ➝ $14.00+21.00%
11/9/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Neutral$9.00 ➝ $12.00+10.80%
11/7/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:00 PM ET.

VTRS Frequently Asked Questions

What is Viatris's stock forecast and purchase recommendation?

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Viatris is $11.00, with a high forecast of $13.00 and a low forecast of $9.00. The consensus rating for Viatris stock is Sell based on the current 2 sell ratings and 1 hold rating for VTRS. Learn more on VTRS's analyst rating history.

Do Wall Street analysts like Viatris more than its competitors?

Analysts like Viatris less than other "medical" companies. The consensus rating for Viatris is Sell while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VTRS compares to other companies.

Does Viatris's stock price have much upside?

According to analysts, Viatris's stock has a predicted upside of 5.80% based on their 12-month stock forecasts.

What analysts cover Viatris?

Viatris has been rated by research analysts at Piper Sandler in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:VTRS) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners